Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new silymarin preparation based on solid dispersion technique.

Ming-feng Qiu1, Wei Jia, Shao-shun Li

  • 1School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

Advances in Therapy
|March 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pig bile powder maintains blood glucose homeostasis by promoting glucagon-like peptide-1 secretion <i>via</i> inhibiting farnesoid X receptor.

World journal of diabetes·2025
Same author

Differences in Fatty Acid Metabolism between MCDD and HFD Induced Metabolic Dysfunction-associated Fatty Liver Disease Model Mice.

Biological procedures online·2025
Same author

Clerodendranthus Spicatus: A review of its active compounds, mechanisms of action, and clinical studies in urinary diseases.

Fitoterapia·2024
Same author

Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.

European journal of medicinal chemistry·2019
Same author

[Determination of mycotoxins in pu-erh tea, black tea, and green tea samples].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2018
Same author

Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.

European journal of medicinal chemistry·2017

New silymarin dripping pills significantly enhance solubility. These novel solid dispersions show a 7.5-11 times faster dissolution rate compared to existing preparations.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • Silymarin, a potent hepatoprotective agent, suffers from poor aqueous solubility, limiting its therapeutic efficacy.
  • Developing advanced drug delivery systems is crucial for improving the bioavailability of poorly soluble compounds like silymarin.

Purpose of the Study:

  • To develop and characterize a novel solid dispersion formulation of silymarin in the form of "dripping pills" to enhance its solubility and dissolution rate.
  • To compare the dissolution performance of the new silymarin dripping pills against established silymarin formulations.

Main Methods:

  • Silymarin dripping pills were prepared using a 1:4 ratio of silymarin to polyethylene glycol 6000 (PEG 6000) via the fusion method.
  • Characterization included assessment of pill size, weight, and silymarin content.

Related Experiment Videos

  • Dissolution rates were evaluated in a pH 1.2 medium and compared with Yiganling Film-Coating Tablet, Yiganling Sugar-Coating Tablet, and Legalon Capsule.

    • Main Results:

    • The prepared silymarin dripping pills were uniformly spherical, 3-4 mm in diameter, with each pill containing 5 mg of silymarin.
    • The dissolution rate, specifically the time for 50% dissolution (T50), of the silymarin dripping pill was significantly higher than the other three commercial preparations.
    • The T50 of the dripping pills was found to be 7.5 to 11 times faster than the comparative formulations.

    Conclusions:

    • Silymarin dripping pills represent a promising solid dispersion formulation for enhancing the solubility and dissolution of silymarin.
    • This novel preparation demonstrates superior dissolution performance compared to conventional silymarin dosage forms.
    • The enhanced dissolution profile suggests improved potential for silymarin bioavailability and therapeutic outcomes.